Dataset Information

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

ABSTRACT: Osteoporosis is a complex disease that affects >10 million people in the United States and results in 1.5 million fractures annually. In addition, the high prevalence of osteopenia (low bone mass) in the general population places a large number of people at risk for developing the disease. In an effort to identify genetic factors influencing bone density, we characterized a family that includes individuals who possess exceptionally dense bones but are otherwise phenotypically normal. This high-bone-mass trait (HBM) was originally localized by linkage analysis to chromosome 11q12-13. We refined the interval by extending the pedigree and genotyping additional markers. A systematic search for mutations that segregated with the HBM phenotype uncovered an amino acid change, in a predicted beta-propeller module of the low-density lipoprotein receptor-related protein 5 (LRP5), that results in the HBM phenotype. During analysis of >1,000 individuals, this mutation was observed only in affected individuals from the HBM kindred. By use of in situ hybridization to rat tibia, expression of LRP5 was detected in areas of bone involved in remodeling. Our findings suggest that the HBM mutation confers a unique osteogenic activity in bone remodeling, and this understanding may facilitate the development of novel therapies for the treatment of osteoporosis.

SUBMITTER: Little RD

PROVIDER: S-EPMC419982 | biostudies-literature | 2002 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Little Randall D RD Carulli John P JP Del Mastro Richard G RG Dupuis Josée J Osborne Mark M Folz Colleen C Manning Susan P SP Swain Pamela M PM Zhao Shan-Chuan SC Eustace Brenda B Lappe Michelle M MM Spitzer Lia L Zweier Susan S Braunschweiger Karen K Benchekroun Youssef Y Hu Xintong X Adair Ronald R Chee Linda L FitzGerald Michael G MG Tulig Craig C Caruso Anthony A Tzellas Nia N Bawa Alicia A Franklin Barbara B McGuire Shannon S Nogues Xavier X Nogues Xavier X Gong Gordon G Allen Kristina M KM Anisowicz Anthony A Morales Arturo J AJ Lomedico Peter T PT Recker Susan M SM Van Eerdewegh Paul P Recker Robert R RR Johnson Mark L ML

American journal of human genetics 20011203 1

Osteoporosis is a complex disease that affects >10 million people in the United States and results in 1.5 million fractures annually. In addition, the high prevalence of osteopenia (low bone mass) in the general population places a large number of people at risk for developing the disease. In an effort to identify genetic factors influencing bone density, we characterized a family that includes individuals who possess exceptionally dense bones but are otherwise phenotypically normal. This high-b ...[more]

PMID: 11741193

Similar Datasets

Project description:BACKGROUND:PKD2-related autosomal dominant polycystic kidney disease (ADPKD) is widely acknowledged to be of milder severity than PKD1-related disease, but population-based studies depicting the exact burden of the disease are lacking. We aimed to revisit PKD2 prevalence, clinical presentation, mutation spectrum, and prognosis through the Genkyst cohort. STUDY DESIGN:Case series, January 2010 to March 2016. SETTINGS & PARTICIPANTS:Genkyst study participants are individuals older than 18 years from 22 nephrology centers from western France with a diagnosis of ADPKD based on Pei criteria or at least 10 bilateral kidney cysts in the absence of a familial history. Publicly available whole-exome sequencing data from the ExAC database were used to provide an estimate of the genetic prevalence of the disease. OUTCOMES:Molecular analysis of PKD1 and PKD2 genes. Renal survival, age- and sex-adjusted estimated glomerular filtration rate. RESULTS:The Genkyst cohort included 293 patients with PKD2 mutations (203 pedigrees). PKD2 patients with a nephrology follow-up corresponded to 0.63 (95% CI, 0.54-0.72)/10,000 in Brittany, while PKD2 genetic prevalence was calculated at 1.64 (95% CI, 1.10-3.51)/10,000 inhabitants in the European population. Median age at diagnosis was 42 years. Flank pain was reported in 38.9%; macroscopic hematuria, in 31.1%; and cyst infections, in 15.3% of patients. At age 60 years, the cumulative probability of end-stage renal disease (ESRD) was 9.8% (95% CI, 5.2%-14.4%), whereas the probability of hypertension was 75.2% (95% CI, 68.5%-81.9%). Although there was no sex influence on renal survival, men had lower kidney function than women. Nontruncating mutations (n=36) were associated with higher age-adjusted estimated glomerular filtration rates. Among the 18 patients with more severe outcomes (ESRD before age 60), 44% had associated conditions or nephropathies likely to account for the early progression to ESRD. LIMITATIONS:Younger patients and patients presenting with milder forms of PKD2-related disease may not be diagnosed or referred to nephrology centers. CONCLUSIONS:Patients with PKD2-related ADPKD typically present with mild disease. In case of accelerated degradation of kidney function, a concomitant nephropathy should be ruled out.

Dataset Information

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Publications

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets